Low expression of BTG1 in newly diagnosed AML treated with decitabine-containing regimen was associated with CR and MRD negativity, suggesting that BTG1 is a potential marker to predict the response to decitabine. This evidence concerns the gene BTG1 and acute myeloid leukemia.